Overview

Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of lenalidomide in the treatment of relapsed or refractory classic Hodgkin lymphoma(cHL).
Phase:
Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborator:
Celgene Corporation
Treatments:
Lenalidomide
Thalidomide